Author

Olivier Rixie

Observed name: O. Rixie

Institution: University of New Mexico

Observed institution: University of New Mexico

OpenAlex ID: A5064965663

Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

2017 · Yousef Zakharia, Robert McWilliams, et al. · Cancer Research · 37

Sunitinib as First-line Treatment for Metastatic Renal Cell Carcinoma (mrcc): Updated Results and Analysis of Prognostic Factors From a Phase Iii Randomised Trial

2008 · S. Oudard, R.J. Motzer, et al. · European Urology Supplements · 4

Works count: 2

Citation count: 41

H-index: 2

I10-index: 1